Anna Michalska-Falkowska
Overview
Explore the profile of Anna Michalska-Falkowska including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
73
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sniadach J, Kicman A, Michalska-Falkowska A, Jonczyk K, Waszkiewicz N
Int J Mol Sci
. 2025 Mar;
26(5).
PMID: 40076424
Currently, the number of e-cigarette and heated tobacco product (HTP) users are steadily increasing, while the number of classic cigarette users are decreasing. The effects of smoking classic cigarettes on...
2.
Sieminska J, Miniewska K, Mroz R, Sierko E, Naumnik W, Kisluk J, et al.
Front Mol Biosci
. 2024 May;
11:1379631.
PMID: 38725870
Discrimination between adenocarcinoma (ADC) and squamous cell carcinoma (SCC) subtypes in non-small cell lung cancer (NSCLC) patients is a significant challenge in oncology. Lipidomics analysis provides a promising approach for...
3.
Dobrzycka M, Sulewska A, Biecek P, Charkiewicz R, Karabowicz P, Charkiewicz A, et al.
Int J Mol Sci
. 2023 Oct;
24(19).
PMID: 37834147
Glaucoma, a neurodegenerative disorder that leads to irreversible blindness, remains a challenge because of its complex nature. MicroRNAs (miRNAs) are crucial regulators of gene expression and are associated with glaucoma...
4.
Charkiewicz R, Sulewska A, Charkiewicz A, Gyenesei A, Galik B, Ramlau R, et al.
Int J Mol Sci
. 2023 Sep;
24(17).
PMID: 37686123
Non-small cell lung cancer (NSCLC) encompasses distinct histopathological subtypes, namely adenocarcinoma (AC) and squamous cell lung carcinoma (SCC), which require precise differentiation for effective treatment strategies. In this study, we...
5.
Michalska-Falkowska A, Niklinski J, Juhl H, Sulewska A, Kisluk J, Charkiewicz R, et al.
Cancers (Basel)
. 2023 Jul;
15(14).
PMID: 37509403
Biobanks are vital for high-throughput translational research, but the rapid development of novel molecular techniques, especially in omics assays, poses challenges to traditional practices and recommendations. In our study, we...
6.
Ciereszko A, Dietrich M, Slowinska M, Nynca J, Ciborowski M, Kaczmarek M, et al.
PLoS One
. 2022 May;
17(5):e0268073.
PMID: 35512017
Lung cancer is responsible for the most cancer-related mortality worldwide and the mechanism of its development is poorly understood. Proteomics has become a powerful tool offering vital knowledge related to...
7.
Ciereszko A, Dietrich M, Slowinska M, Nynca J, Ciborowski M, Kisluk J, et al.
PLoS One
. 2019 Oct;
14(10):e0223840.
PMID: 31622403
A comparative analysis of blood samples (depleted of albumin and IgG) obtained from lung cancer patients before chemotherapy versus after a second cycle of chemotherapy was performed using two-dimensional difference...
8.
Michalska-Falkowska A, Sacha P, Grzes H, Hauschild T, Wieczorek P, Ojdana D, et al.
Postepy Hig Med Dosw (Online)
. 2017 Aug;
71(0):589-594.
PMID: 28791953
The effectiveness of carbapenems, considered as last-resort antimicrobials in severe infections, becomes compromised by bacterial resistance. The production of metallo-β-lactamases (MBLs) is the most significant threat to carbapenems activity among...
9.
Niklinski J, Kretowski A, Moniuszko M, Reszec J, Michalska-Falkowska A, Niemira M, et al.
Adv Med Sci
. 2017 Jun;
62(2):405-413.
PMID: 28646744
Personalized and precision medicine is gaining recognition due to the limitations by standard diagnosis and treatment; many areas of medicine, from cancer to psychiatry, are moving towards tailored and individualized...
10.
Charkiewicz R, Niklinski J, Claesen J, Sulewska A, Kozlowski M, Michalska-Falkowska A, et al.
Transl Oncol
. 2017 Apr;
10(3):450-458.
PMID: 28456114
Advances in molecular analyses based on high-throughput technologies can contribute to a more accurate classification of non-small cell lung cancer (NSCLC), as well as a better prediction of both the...